Center for Structural Biology
CSB in a nutshell
Science directors: Jan Steyaert & Han Remaut
Structural biology is undergoing a major leap forward in defining three-dimensional submicroscopic structures thanks to cryo-electron microscopy (cryo-EM) and novel approaches to imaging in cell biology. CSB is an integrated center that supports the major methodologies for structural biology (biophysics, NMR, X-ray and cryoEM) complemented with unique and differentiating platforms (Nanobody technology). This interdisciplinary and integrative approach gives us enormous leverage to produce excellent educational opportunities, carry out grand challenge science, and stimulate research-based economic development.
Labs
Name
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-VUB Center for Structural Biology - visiting scientist
Impact on society
Nanobodies, our legacy
In 1989, Professor Raymond Hamers' laboratory at VUB discovered a new type of antibody in the blood of a dromedary. This led to the development of single-domain antibodies known as VHHs or Nanobodies® by former VIB researcher Serge Muyldermans. These tiny antibody fragments have resulted in the establishment of five VIB spin-off companies, including Ablynx, Biotalys, Confo Therapeutics, ExeVir Bio, and Animab. These companies are exploring the potential of VHHs as therapeutics for human and livestock diseases, crop protection, and drug discovery. Ongoing research at VIB continues to contribute to technological innovations in the VHH field.
Read more
Inhalable biologics to control respiratory infections
Developing pan-influenza neutralizing biologics to treat and prevent viral pneumonia in the Ibcori project.
Read more